|Bid||66.78 x 4000|
|Ask||66.63 x 3100|
|Day's Range||64.69 - 67.18|
|52 Week Range||53.63 - 71.70|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||123.07|
|Forward Dividend & Yield||1.44 (2.15%)|
|Ex-Dividend Date||Feb 24, 2022|
|1y Target Est||N/A|
New drugs from Eli Lilly and Novo Nordisk have shown striking results in studies. If insurers step up to back them, the drugs—and the stocks—could take off.
The FDA has approved Daiichi Sankyo (OTC: DSNKY) and AstraZeneca plc's (NASDAQ: AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory
Large corporations are jumping on the "green" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible. In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid. But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.